← Leaderboards
Thomas W. Gardner
Pennsylvania State Univ Hershey Med Ctr
$6,124,476
Attributed
$17,824,823
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6M · FY2005–19$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$17,824,823 · 7
By mechanism
DP3$5,514,789 · 1
R01$4,959,081 · 2
R24$4,538,552 · 1
K12$2,795,089 · 1
M01$17,312 · 2
Top collaborators
- Steve F Abcouwer9 shared
- Paul P Lee7 shared
- Frank C Brosius5 shared
- Eva L Feldman5 shared
- Subramaniam Pennathur5 shared
- H V Jagadish4 shared
- Matthias Kretzler4 shared
- Kumar Sharma4 shared
Most similar at Pennsylvania State Univ Hershey Med Ctr
Same institution · by research overlap
- Richard S. Legro$15,817,930
- Leonard S Jefferson$13,600,854
- Michael D. Dennis$5,943,850
Others in their field
Top investigators on “Diabetic Retinopathy”
- John M Lachin · George Washington University$140,240,809
- David M Nathan · Massachusetts Institute Of Technology$123,291,647
- Rose A Gubitosi-Klug · Case Western Reserve University$71,942,336
- Rohit Varma · University Of Southern California$56,244,772
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Adam R Glassman · Jaeb Center For Health Research, Inc.$50,075,374
Research focus
Diabetic RetinopathyDiabetes MellitusVisionHyperglycemiaPersonsRegulationRetinaBaseLeadRetinalDiabetic MousePathway InteractionsExhibitsPathogenesisAreaFundingMediatingProteinsInsulinInterdisciplinary StudyPhosphorylationCellsDiabeticCell Death
Grant awards (27)
Michigan Vision Clinician Scientist Development Program$469,197
K12 · FY2019 · EY · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,374,854
R24 · FY2018 · DK
Regulation of Retinal Cell Death in Diabetes$557,618
R01 · FY2018 · EY · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$390,000
R24 · FY2018 · DK
Michigan Vision Clinician Scientist Development Program$304,239
K12 · FY2018 · EY · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,378,119
R24 · FY2017 · DK
Regulation of Retinal Cell Death in Diabetes$557,618
R01 · FY2017 · EY · contact PI
Michigan Vision Clinician Scientist Development Program$306,748
K12 · FY2017 · EY · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,395,579
R24 · FY2016 · DK
Regulation of Retinal Cell Death in Diabetes$557,618
R01 · FY2016 · EY · contact PI
Michigan Vision Clinician Scientist Development Program$459,121
K12 · FY2016 · EY · contact PI
Regulation of Retinal Cell Death in Diabetes$571,370
R01 · FY2015 · EY · contact PI
Michigan Vision Clinician Scientist Development Program$337,542
K12 · FY2015 · EY · contact PI
Michigan Vision Clinician Scientist Development Program$459,121
K12 · FY2014 · EY · contact PI
Michigan Vision Clinician Scientist Development Program$459,121
K12 · FY2013 · EY · contact PI
Regulation of Retinal Cell Death in Diabetes$411,025
R01 · FY2013 · EY · contact PI
Regulation of Retinal Cell Death in Diabetes$448,980
R01 · FY2012 · EY · contact PI
Tissue-Specific Metabolic Reprogramming in Diabetic Complications$5,514,789
DP3 · FY2011 · DK
Regulation of Retinal Cell Death in Diabetes$445,687
R01 · FY2011 · EY · contact PI
Regulation of Retinal Cell Death in Diabetes$292,500
R01 · FY2010 · EY · contact PI
Regulation of Retinal Cell Death in Diabetes$159,151
R01 · FY2010 · EY · contact PI
IMMUNOTHERAPY WITH AUTOLOGOUS ANTIGEN PRESENTING CELLS LOADED WITH PA2024$442
M01 · FY2005 · RR
Mechanisms of Retinal Vascular Permeability in Diabetes$351,119
R01 · FY2004 · EY
Retinal &Peripheral Nerve in Insulin Resistance &PCOS$16,870
M01 · FY2004 · RR
MECHANISMS OF RETINAL VASCULAR PERMEABILITY IN DIABETES$205,977
R01 · FY2002 · EY
MECHANISMS OF RETINAL VASCULAR PERMEABILITY IN DIABETES$206,373
R01 · FY2001 · EY
MECHANISMS OF RETINAL VASCULAR PERMEABILITY IN DIABETES$194,045
R01 · FY2000 · EY